Combination of small-molecule MCL1 inhibition and TKI treatment synergistically induces concurrent strong apoptotic and variable levels of GSDME-dependent pyroptotic cell death in CML cell lines. This evidence concerns the gene GSDME and chronic myelogenous leukemia, BCR-ABL1 positive.